Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MiMedx GroupMDXG +1.15%57 EV-to-EBITDA is 9.54 as of Jul. 29, 2026, which is 6% below its 10-year median of 10.19. GuruFocus rates MDXG with a GF Score™ of 57/100 and a GF Value™ of $6.68 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 407 Biotechnology companies, MiMedx Group ranks better than 53.81% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, MiMedx Group's enterprise value is $515.4 Mil.
MiMedx Group's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $54.0 Mil. Therefore, MiMedx Group's EV-to-EBITDA for today is 9.54.
The historical rank and industry rank for MiMedx Group's EV-to-EBITDA or its related term are showing as below:
MDXG'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -371.6 Med: 10.19 Max: 159.62
Current: 9.54
During the past 13 years, the highest EV-to-EBITDA of MiMedx Group was 159.62. The lowest was -371.60. And the median was 10.19.
MDXG's EV-to-EBITDA is ranked better than 53.81% of 407
companies
in the Biotechnology industry
Industry Median: 11.7
vs MDXG: 9.54
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
MiMedx Group (NAS:MDXG) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
MiMedx Group's PE Ratio (TTM) for today is calculated as:
MiMedx Group's share price for today is $4.415.
MiMedx Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.200.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for MiMedx Group's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, MiMedx Group's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MiMedx Group EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MiMedx Group's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where MiMedx Group's EV-to-EBITDA falls into.
MiMedx Group's current Enterprise Value is $515.4 Mil.
MiMedx Group's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $54.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MiMedx Group (MDXG) has a EV-to-EBITDA of 9.54 as of Jul. 29, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on MiMedx Group. This is near median its historical median of 10.19. According to the industry distribution chart, MiMedx Group ranks #188 out of 407 companies in the Biotechnology industry, placing it in the top 46.2%.
Is MiMedx Group's EV-to-EBITDA too high?
MiMedx Group's current EV-to-EBITDA of 9.54 is near median its 10-year median of 10.19. The Biotechnology industry median EV-to-EBITDA is 11.70. MiMedx Group's value of 9.54 is 18.5% below this industry median. Based on the distribution chart, MiMedx Group ranks #188 out of 407 companies in the Biotechnology industry, which is above the industry midpoint. Overall, MiMedx Group has a GF Score™ of 57/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does MiMedx Group's EV-to-EBITDA compare to RGNX and ACHV?
According to the Biotechnology industry distribution chart, MiMedx Group ranks #188 out of 407 companies for EV-to-EBITDA. This puts MiMedx Group in the upper half of its industry. The industry median EV-to-EBITDA is 11.70. MiMedx Group's value of 9.54 is 18.5% below this benchmark. While the company's 10-year median is 10.19 vs. the industry median of 11.70, MiMedx Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 11.70, based on 407 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MiMedx Group's current EV-to-EBITDA of 9.54 is 18.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on MiMedx Group. For the Biotechnology industry, the median EV-to-EBITDA is 11.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MiMedx Group's current EV-to-EBITDA is 9.54, which is near median its own 10-year median of 10.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MiMedx Group stock overvalued right now?
Based on GuruFocus' analysis, MiMedx Group (MDXG) is currently considered Significantly Undervalued. The stock's GF Value™ is $6.68, compared to a current price of $4.42 — trading 33.9% below its estimated fair value. The current EV-to-EBITDA is 9.54, which is near median its 10-year median of 10.19 and 18.5% below the Biotechnology industry median of 11.70. MiMedx Group's overall GF Score™ is 57/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For MiMedx Group (MDXG), the current EV-to-EBITDA is 9.54 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MiMedx Group (MDXG) Overvalued in 2026?
Based on GuruFocus' analysis, MiMedx Group stock appears to be undervalued.
The current stock price of $4.42 is trading 33.9% below its estimated GF Value™ of $6.68.
GuruFocus considers MiMedx Group to be Significantly Undervalued.
Key valuation signals for MDXG:
EV-to-EBITDA: 9.54 (near median its 10-year median of 10.19)
GF Value™: $6.68 vs. price of $4.42 (33.9% below fair value)
Industry Position: 18.5% below the Biotechnology median (#188 of 407)
No single metric tells the full story. See the MDXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
57GF Score
Get the complete analysis for MDXG
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDXG has been successfully added to your 
